PetCure Oncology says it has now treated 10,000 patients

PetCure Oncology said it has now treated 10,000 patients with radiation therapy, marking a decade of growth for a company that built its model around expanding access to stereotactic radiation therapy beyond academic centers and into partner specialty hospitals. In its January 7 announcement, the company framed the milestone as evidence that advanced radiation oncology has become a more realistic referral option for community veterinarians, not just a geographically limited specialty service. PetCure, which operates within the Thrive Pet Healthcare network, has previously said it reached 8,000 treated pets in April 2024, and its broader messaging has emphasized shorter stereotactic protocols, telehealth-supported case review, and a growing national footprint. (petcureoncology.com)

Why it matters: For veterinary professionals, the bigger story isn’t just the round number. It’s the continued normalization of referral pathways for radiation oncology at a time when specialist access remains uneven. PetCure has argued that stereotactic radiation can reduce treatment from the 15 to 21 fractions typical of conventional protocols to as few as one to three sessions, which can lower the logistical burden on pet parents and reduce repeated anesthesia events for appropriate cases. That doesn’t make stereotactic therapy the right fit for every tumor, but it does reflect how private-network models are reshaping where advanced cancer care is available and how primary care teams discuss options earlier in the case workup. (petcureoncology.com)

What to watch: Watch for whether PetCure’s next phase centers on new site openings and platform upgrades, including its planned early-2026 Seattle debut of Empyrean’s Sirius radiation system. (empyreanmed.com)